{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Disease control was defined as a best overall response (BOR) of confirmed CR or PR or having stable disease (SD) (without subsequent cancer therapy) maintained for greater than or equal to (\\>=) 14 weeks (study week 15) from first IP. Disease control rate at study week 15 weeks (DCR-15) was defined as the percentage of participants who had disease control at study week 15 weeks. This outcome measure was assessed only for substudy 1 Part A.","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Response evaluable set included all dosed participants who had measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"15 weeks","title":"Disease Control Rate (DCR) at 15 Weeks","type":"SECONDARY","unitOfMeasure":"Participants"}